Median OS 13.2 vs 6.7 months, HR 0.40, in pretreated metastatic pancreatic ductal adenocarcinoma against standard chemotherapy. The era of targeted therapy in pancreatic cancer has finally arrived.

My reaction-diffusion model tried to answer whether the active metabolite of PALI-2108 could penetrate Crohn's strictures but rested on untested assumptions. Phase 1b ileal pharmacokinetics, pharmacodynamics, and endoscopic data from five fibrostenotic Crohn's patients update the priors.

A computational five-compartment pharmacokinetic model built on published parameters suggests that daily oral levosimendan delivers higher and substantially more stable free drug exposure than the weekly IV infusions behind the significant 6MWD improvement in Phase 2.

AMPLIFY-7P and REGAL both face delayed readouts as events accumulate slower than projected. A comparison of trial design, mechanistic evidence, and immune correlates, and why my conviction behind ELI-002 in PDAC and GPS in CR2 AML is not equal.

SELLAS has disclosed enough about its Phase 3 REGAL trial to collapse the GPS investment thesis into a single question: what is the median overall survival in the control arm? Of all permitted BAT maintenance options, only venetoclax might plausibly push it beyond historical norms.

A Johns Hopkins Phase 1 trial of a pooled mKRAS vaccine with dual checkpoint blockade strengthens the case that mKRAS peptides generate durable, cross-reactive T cell immunity correlating with disease-free survival in resected pancreatic cancer, consistent with Elicio's AMPLIFY-201 data.

The readout of AMPLIFY-7P for ELI-002 7P in pancreatic cancer was expected by late 2025. Fewer events than projected pushed it to H1 2026. Monte Carlo simulation maps this delay onto control-arm survival and hazard ratio, with efficacy scenarios fitting 2–3× better.

PALI-2108's Phase 1b data for ulcerative colitis are promising, but UC is mucosal while FSCD is transmural. A computational reaction-diffusion model explores whether PALI-2108 can penetrate Crohn's strictures deeply enough to intercept fibrosis early.

Recent research from Mariano Barbacid’s lab demonstrates that simultaneously inhibiting KRAS, EGFR, and STAT3 leads to durable pancreatic cancer eradication in mice. These findings might provide a biological rationale for a partnership between Revolution Medicines and Kymera Therapeutics.

Elicio Therapeutics is developing an off-the-shelf therapeutic mKRAS vaccine for pancreatic cancer. Phase 1 showed 84% T-cell response correlating with prolonged survival. Phase 2 data expected in H1 2026 will determine whether this approach can transform adjuvant therapy.